One PR has been deleted from the website. VANCO
Post# of 148181
(Total Views: 420)
Posted On: 03/14/2020 11:03:52 AM
One PR has been deleted from the website.
VANCOUVER, Washington, March 12, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (CYDY), (“CytoDyn” or the “Company"
, a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the FDA recommended that the Company request a preliminary Breakthrough Therapy designation meeting. Meanwhile, the Company continues reporting very positive data for its mTNBC and MBC patients.
Why was it deleted?
VANCOUVER, Washington, March 12, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (CYDY), (“CytoDyn” or the “Company"
, a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the FDA recommended that the Company request a preliminary Breakthrough Therapy designation meeting. Meanwhile, the Company continues reporting very positive data for its mTNBC and MBC patients. Why was it deleted?
(0)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼